Literature DB >> 19889120

Interleukin (IL)-31 induces pro-inflammatory cytokines in human monocytes and macrophages following stimulation with staphylococcal exotoxins.

S Kasraie1, M Niebuhr, T Werfel.   

Abstract

BACKGROUND: IL-31 is a cytokine expressed by T cells following activation with cytokines or staphylococcal exotoxins. A major function of IL-31 in atopic dermatitis (AD) is the induction of pruritus in the skin via the IL-31 receptor on sensory nerve cells. However, the regulation of the IL-31 receptor and pro-inflammatory functions of IL-31 in human monocytes and monocyte-derived cells are yet to be studied in detail.
OBJECTIVE: To investigate the regulation and function of IL-31 receptors in resting and activated human monocytes, macrophages and dendritic cells.
METHODS: Human monocytes, macrophages and dendritic cells were stimulated with staphylococcal exotoxins (SEB, alpha-toxin) or cytokines (IFN-gamma, IL-13). IL-31RA expression and regulation were then investigated at both the mRNA and the protein level. Subsequently, functional effects of IL-31 stimulation on cytokine secretion were measured at the protein level.
RESULTS: Staphylococcal exotoxins significantly up-regulated IL-31RA expression on monocytes and macrophages but not on dendritic cells at both the mRNA and the protein level. IL-31 enhanced the secretion of IL-1beta, IL-6 and IL-18 and up-regulated CD86 expression. In patients with AD, functional IL-31RA was also detected following stimulation of PBMC with IFN-gamma. However, this was not observed in healthy individuals.
CONCLUSION: IL-31 induces pro-inflammatory effects in activated human monocytes and macrophages. This may have implications for cutaneous inflammation in eczema where an over-expression of IL-31 has been described previously. Moreover, our findings provide a new link between staphylococcal colonization and the worsening of inflammation via IL-31. Further therapeutic considerations may include IL-31 as a target in AD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19889120     DOI: 10.1111/j.1398-9995.2009.02255.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  33 in total

Review 1.  The role of the histamine H4 receptor in atopic dermatitis.

Authors:  Susanne Mommert; Maria Gschwandtner; Ralf Gutzmer; Thomas Werfel
Journal:  Curr Allergy Asthma Rep       Date:  2011-02       Impact factor: 4.806

Review 2.  Pruritus in cutaneous T-cell lymphoma: a review.

Authors:  Kristen Ahern; Elaine S Gilmore; Brian Poligone
Journal:  J Am Acad Dermatol       Date:  2012-01-30       Impact factor: 11.527

Review 3.  Role of dendritic cells in atopic dermatitis: an update.

Authors:  Thomas Bieber; Natalija Novak; Nadine Herrmann; Nadine Herrman; Susanne Koch
Journal:  Clin Rev Allergy Immunol       Date:  2011-12       Impact factor: 8.667

4.  Th2 Cytokines Augment IL-31/IL-31RA Interactions via STAT6-dependent IL-31RA Expression.

Authors:  Ramakrishna Edukulla; Brijendra Singh; Anil G Jegga; Vishwaraj Sontake; Stacey R Dillon; Satish K Madala
Journal:  J Biol Chem       Date:  2015-04-06       Impact factor: 5.157

5.  Distinctive cytokine, chemokine, and antibody responses in Echinococcus multilocularis-infected patients with cured, stable, or progressive disease.

Authors:  Xiangsheng Huang; Beate Grüner; Christian J Lechner; Peter Kern; Peter T Soboslay
Journal:  Med Microbiol Immunol       Date:  2014-02-09       Impact factor: 3.402

6.  Unique immunomodulatory effects of azelastine on dendritic cells in vitro.

Authors:  S Schumacher; M Kietzmann; H Stark; W Bäumer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-08-15       Impact factor: 3.000

Review 7.  Molecular biology of atopic dermatitis.

Authors:  Zhanglei Mu; Yan Zhao; Xiaojing Liu; Christopher Chang; Jianzhong Zhang
Journal:  Clin Rev Allergy Immunol       Date:  2014-10       Impact factor: 8.667

Review 8.  Interleukin-31: a novel diagnostic marker of allergic diseases.

Authors:  Anja Rabenhorst; Karin Hartmann
Journal:  Curr Allergy Asthma Rep       Date:  2014-04       Impact factor: 4.806

9.  Anti-IL-31 receptor antibody is shown to be a potential therapeutic option for treating itch and dermatitis in mice.

Authors:  K Kasutani; E Fujii; S Ohyama; H Adachi; M Hasegawa; H Kitamura; N Yamashita
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

10.  The association of interleukin-31 polymorphisms with interleukin-31 serum levels and risk of systemic lupus erythematosus.

Authors:  Hua-Tuo Huang; Jian-Ming Chen; Jing Guo; Yan Lan; Ye-Sheng Wei
Journal:  Rheumatol Int       Date:  2016-01-14       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.